Women with early stage breast cancer won a new gene test Tuesday to help predict whether they'll relapse in five or 10 years, information that could influence how aggressively they fight that initial tumor.
The MammaPrint test isn't the first such predictor for breast cancer to hit the U.S. market, but it is the first to win formal approval from the
Food and Drug Administration.
Read More